A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery.
Summary
In a 2010-patient, multinational, single-blind RCT, acute normovolemic hemodilution did not reduce the proportion of cardiac surgical patients receiving allogeneic red-cell transfusion compared with usual care. Safety outcomes were similar, with a small numerical increase in reoperation for bleeding in the ANH arm.
Key Findings
- Allogeneic red-cell transfusion occurred in 27.3% (ANH) vs 29.2% (usual care), RR 0.93 (95% CI 0.81–1.07), P=0.34
- Reoperation for bleeding: 3.8% (ANH) vs 2.6% (usual care)
- 30-day/in-hospital mortality similar: 1.4% (ANH) vs 1.6% (usual care)
Clinical Implications
Routine ANH for transfusion reduction in cardiac surgery is not supported; programs should reassess ANH use and focus on multimodal blood conservation strategies with proven benefit.
Why It Matters
This high-quality RCT provides definitive evidence against routine ANH to reduce transfusions in modern cardiac surgery, guiding resource allocation and protocol design.
Limitations
- Single-blind design may introduce performance bias
- Slight numerical increase in reoperation for bleeding warrants careful interpretation
Future Directions
Investigate targeted subgroups or protocol variations where ANH might confer benefit, and compare against alternative blood conservation strategies.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Large multicenter randomized controlled trial provides highest-level evidence
- Study Design
- OTHER